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The use of small interfering RNA (siRNA) is a great promise for the treatment of 
different mucosal cancers but their physico-chemical properties make these 
administration challenging. The complexation of siRNA with liposomes and 
polyethylene glycol (PEG) is actually the best strategy to develop muco-penetrating 
nanoparticles. However, the addition of PEG may interfere with the transfection 
process of lipoplexes and with the releasing of siRNA into the cytoplasm due to a steric 
hindrance. The aim of this project is to determine which type and which density of PEG 
allow to develop an efficient and an atoxic lipoplexes which can also penetrate through 
the vaginal mucus. In this this study, two active siRNA are selected in the context of 
cervical (pre)neoplastic lesions induced by the infection of different high-risk Human 
Papillomavirus (HR-HPV). 
PEGylated lipoplexes were made of DOTAP/Cholesterol/DOPE (molar ratio 
1/0.75/0.5) liposomes and complexed with siRNA at a N/P ratio of 2.5. DSPE-PEG2000 
and Ceramide-PEG2000 were added by post insertion technique (20-30-50% of DOTAP 
in molar ratio). Physico-chemical properties were characterized in water as well as in 
mucin solution, and mRNA knockdown were studied by qRT-PCR. Biological activities 
of siRNA-antiE7 and anti-MCL1 were tested on different HPV16 and HPV18 cell lines. 
Then, the penetration and efficiency of formulations on a 3D-cervical model lesion were 
performed. Finally, PEGylated lipoplexes were administrated into the cervical vaginal 
tract of female C57Bl/6 mice to study the muco-penetration in vivo. 
In this study, we have found that both the type and the percentage of PEG added 
around lipoplexes are crucial factors in order to develop efficient lipoplexes. The 
Ceramide-PEG2000 (20%) was selected and induced a significant mRNA knockdown. 
This formulation induces the decreasing of proliferation and the induction of apoptosis 
of HPV16 and HPV18 positive cells. After validating the colloidal stability of PEGylated 
lipoplexes in mucus, the penetration and the delivery of siRNA into different mucosal 
models have also been validated. Moreover, this formulation was effective on a 3D-
cervical lesion model HPV16 positive. Since the vaginal administration of this 
nanoparticle allows a complete coverage of the mucosal epithelium, we propose this 
nanocarrier as a promising therapeutic candidate for a wide range of HPV-induced 
mucosal cancers. 
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